Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of APC148 in Healthy Adults
NCT06360640Phase 1Completed
- Sponsor
- AdjuTec Pharma AS
- Start
- Sep 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APC148 in bacterial infection (12 cohorts), sponsored by AdjuTec Pharma AS. Primary endpoints: Incidence and intensity of adverse events (AEs), Incidence and intensity of serious adverse events (SAEs) and 6 more. Started Sep 2024; status: completed.
02
Drugs
APC148
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06360640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360640.